SLITRK5 is a cellular protein whose normal function appears to suppress bone formation and could be a potential new target for the treatment ofosteoporosis, according to a collaborative study conducted by Weill Cornell Medicine and NewYork-Presbyterian researchers.
Cells manifesting the SLITRK5 protein are marked with magenta (left) and a bone-forming osteoblast marker in green (center). These markers were observed in the cancellous bone in the medulla space (top) or on the outer layer covering the bone (bottom). The overlap between these two markers (right) shows that SLITRK5 is found in bone-forming osteoblasts but not in other cell types, helping to make SLITRK5 a target for skeletal disease treatment. Credit: Dr. Matthew Greenblatt and Dr. Jun Sun
There Research was published in the scientific journal Nature Communications.
Read Also
- Puebla Congress ignored us: Voice of the Disappeared Jul 17, 2021
- Wall Street reacted positively to the new economic data and closed with gains again May 26, 2022
- First complaint against the Government for endorsing before the Court of Accounts Jul 23, 2021
- Hyundai Tucson Plug-in Hybrid, features and prices Jul 1, 2021
- Masterpiece by painter Gustav Klimt sprayed with black liquid by environmental activists Nov 15, 2022
- World Cup 2022: “Return to the daronne”, Seine-Saint-Denis launches its campaign against sports betting Nov 19, 2022
- England thrashes Ukraine to reach the semifinals of the Euro Cup – ISTOÉ DINHEIRO Jul 4, 2021